The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly expanding into the realm of oral medications. With Novo Nordisk’s oral Wegovy officially authorized in the European Union (EU) as the first oral GLP-1 receptor agonist for weight management, the competitive landscape for weight-loss therapeutics is widening significantly from injections to daily pills.
Novo Nordisk announced on July 15 (local time) that the European Commission has approved the commercial sale of oral Wegovy (active ingredient: semaglutide) 25 mg for adults living with obesity or overweight. The decision follows a positive recommendation issued in May by the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA). Oral Wegovy was first approved in the United States in December last year and has been commercially available there since January this year. The EU authorization marks the fifth regional approval for the pill, following successful clearances in the U.S., the United Kingdom, the United Arab Emirates, and Bahrain.
The European authorization covers adults with obesity who have a body mass index (BMI) of 30 kg/m² or higher, as well as overweight adults with a BMI between 27 kg/m² and 30 kg/m² who present with at least one weight-related comorbidity, such as hypertension, dyslipidemia, type 2 diabetes, or cardiovascular disease. The medication is indicated for weight loss and long-term weight management when used in conjunction with a reduced-calorie diet and increased physical activity.
While oral Wegovy utilizes the exact same active ingredient as the existing once-weekly subcutaneous injection, it is formulated as a daily pill. The oral dosing regimen requires strict patient compliance: individuals must fast for at least 8 hours before taking the medication, and they must avoid consuming food, beverages, or other oral medications for 30 minutes afterward. While the pill significantly reduces the psychological aversion associated with needles, it demands rigorous adherence to this fixed daily schedule.
Mechanistically, semaglutide works by mimicking the action of the naturally occurring GLP-1 hormone released by the body after meals, which effectively suppresses appetite, increases feelings of fullness, and reduces overall caloric intake to support sustained weight loss.
The Phase 3 clinical trial supporting the EU approval enrolled 307 adults who were obese or overweight with at least one weight-related comorbidity. Participants received either oral Wegovy or a placebo for 64 weeks alongside a reduced-calorie diet and regular exercise. In an efficacy analysis that included patients who discontinued treatment, the Wegovy group achieved an average weight loss of 13.61%, compared to just 2.18% in the placebo group. Furthermore, 76.3% of patients taking oral Wegovy lost 5% or more of their body weight, compared to 30.5% in the placebo arm. The most common adverse events reported were gastrointestinal issues—including nausea, diarrhea, constipation, abdominal pain, indigestion, and vomiting—aligning with the known safety profile of the injectable version.
With this strategic milestone, Novo Nordisk enters Europe’s oral GLP-1 obesity market ahead of its chief rival, Eli Lilly. Eli Lilly’s oral GLP-1 candidate, Foundayo (active ingredient: orforglipron), has achieved regulatory approval in the United States, but its authorization process is still pending in Europe. Unlike semaglutide, Foundayo is a non-peptide, small-molecule compound, which allows patients to take it without any strict fasting or fluid-intake restrictions.
Simultaneously, the European Commission approved a high-dose, 7.2 mg formulation of Novo Nordisk's once-weekly injectable Wegovy alongside the oral option. This high-dose injection is engineered to drive additional weight loss by scaling up the dosage far beyond the current maximum maintenance dose of 2.4 mg. In the 72-week Phase 3 STEP UP study, patients who maintained the 7.2 mg injection regimen achieved an average weight loss of 20.7%, compared to 17.5% in the 2.4 mg group and 2.4% in the placebo group. Clinicians note that the 20% range weight reduction stems entirely from this high-dose injectable trial, rather than the oral pill data.
By simultaneously locking in a convenient oral option and a potent, high-dose injectable, Novo Nordisk has significantly diversified its metabolic pipeline, allowing healthcare providers and patients to tailor their obesity therapy based on specific dosing preferences and therapeutic weight-loss goals.
